OBI Pharma, Inc.

Taipei Exchange 4174.TWO

OBI Pharma, Inc. Total Non-Current Liabilities for the year ending December 31, 2023: USD 16.02 M

OBI Pharma, Inc. Total Non-Current Liabilities is USD 16.02 M for the year ending December 31, 2023, a 77.67% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

OBI Pharma, Inc. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 9.02 M, a -13.42% change year over year.
OBI Pharma, Inc. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 10.42 M, a 15.52% change year over year.
OBI Pharma, Inc. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 9.02 M, a 4.07% change year over year.
OBI Pharma, Inc. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 8.66 M, a 100.38% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Taipei Exchange: 4174.TWO

OBI Pharma, Inc.

CEO	Dr. Heidi Wang Ph.D.
IPO Date	Dec. 12, 2012
Location	Taiwan
Headquarters	No. 3, Park Street
Employees	260
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Cosmetics Drugstores & Retail Pharmacies Pharmaceuticals Vaccines

Description

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898 and OBI-998 drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.

Key trends

Past 5 years